CS Cancer Solutions - Structured Oncology Intelligence
South Africa flag

South Africa Cancer Research

Leading African Cancer Research with Focus on Regional Cancer Patterns

Leading

African Research Hub

Continental leadership

Pioneer

HIV-Cancer Research

Global expertise

Growing

Clinical Trial Infrastructure

International collaboration

Major Research Breakthroughs

Pioneering HIV-Related Cancer Research

2023-2024

South African researchers are global leaders in understanding and treating cancers associated with HIV/AIDS, including Kaposi sarcoma and cervical cancer.

University of Cape Town

Impact:

Advancing treatment strategies for HIV-positive cancer patients worldwide

Esophageal Cancer Research in High-Incidence Populations

2023

South Africa is conducting groundbreaking research on esophageal cancer, which has high incidence rates in Southern and Eastern Africa.

University of the Witwatersrand

Impact:

Understanding cancer patterns unique to African populations

Expanding Clinical Trial Infrastructure

Ongoing

South Africa has become a key site for international oncology trials, offering access to diverse patient populations and growing research capabilities.

Multiple South African cancer centers

Impact:

Bringing global innovations to African patients and informing worldwide research

Cervical Cancer Prevention and HPV Research

2022-2024

South African researchers are advancing HPV vaccination programs and cervical cancer screening in resource-limited settings.

National Health Laboratory Service

Impact:

Reducing cervical cancer burden across sub-Saharan Africa

Cancer Genomics in African Populations

2023

South Africa is establishing genomic research programs to understand cancer biology in African populations, addressing historic underrepresentation in cancer genomics.

South African Medical Research Council

Impact:

Improving precision medicine for African ancestry populations globally

Leading Research Institutions

University of Cape Town Cancer Centre

Cape Town

Leading African cancer research institution. Comprehensive oncology research with focus on HIV-related cancers and regional cancer patterns.

Key Specialties:

HIV-Related Cancers
Clinical Trials
Infectious Disease-Cancer Interactions

University of the Witwatersrand Cancer Research Initiative

Johannesburg

Major research center advancing understanding of esophageal, cervical, and other cancers prevalent in African populations.

Key Specialties:

Esophageal Cancer
Cervical Cancer
Cancer Epidemiology

South African Medical Research Council

Cape Town

National research organization coordinating cancer research efforts and establishing genomics programs across South Africa.

Key Specialties:

Cancer Genomics
Population Health
Prevention Research
Active Clinical Trials in South Africa

South Africa serves as a key site for international oncology research in Africa

Kaposi Sarcoma Targeted Therapy Trial

Phase 2

International trial testing novel targeted therapies for Kaposi sarcoma in HIV-positive patients.

University of Cape Town
Active recruitment

Cervical Cancer Immunotherapy Study

Phase 3

Multi-center trial evaluating immunotherapy for advanced cervical cancer in sub-Saharan Africa.

Multiple South African sites
Active recruitment

Esophageal Cancer Prevention and Early Detection Program

Observational

Registry study identifying risk factors and screening strategies for esophageal cancer in high-incidence regions.

University of the Witwatersrand
Ongoing enrollment

Want to learn about more clinical trials in South Africa? Search our database.

Clinical Trials in South Africa

Registry-listed trials for South Africa currently tracked in our database, sourced from public trial registries.

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Phase II
Recruiting
NCT07409103
View registry record

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Phase II
Recruiting
NCT07409103
Active Rheumatoid Arthritis
View registry record

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Phase II
Recruiting
NCT07409103
View registry record

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Phase II
Recruiting
NCT07409103
View registry record

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Investigate the Safety and Efficacy of ELV001 as Add-on Therapy in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate and Tumor Necrosis Factor Inhibition (START SYNERGY)

Phase II
Recruiting
NCT07409103
View registry record

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase II
Recruiting
NCT07125872
View registry record

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase II
Recruiting
NCT07125872
View registry record

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase II
Recruiting
NCT07125872
View registry record

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase II
Recruiting
NCT07125872
Relapsed B-Cell Non Hodgkin Lymphoma
View registry record

Open Label, Phase 2 Study of CD19 t-haNK and N-803 in Combination With Rituximab in Participants With Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma

Phase II
Recruiting
NCT07125872
View registry record

A Phase-3b, Partially Double-blind, Randomized, Multi-country Clinical Study to Evaluate the Immunogenicity,Safety, and Reactogenicity of SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

Phase III
Active, not recruiting
NCT06281119
View registry record

A Phase-3b, Partially Double-blind, Randomized, Multi-country Clinical Study to Evaluate the Immunogenicity,Safety, and Reactogenicity of SIIPL qHPV Vaccine (CERVAVAC®) in Women Living With HIV Aged 15-25 Years

Phase III
Active, not recruiting
NCT06281119
Human Papillomavirus Infection
View registry record

Latest Research Ecosystem Developments

South Africa — South Africa's oncology ecosystem is experiencing a period of strategic growth through international research partnerships, expanded diagnostic access, and the introduction of advanced immunotherapies.

Updated October 14, 2026

Registration of Breakthrough Immunotherapy for Nasopharyngeal Carcinoma

In August 2026, a new PD-1 inhibitor was registered in South Africa for the treatment of recurrent or metastatic nasopharyngeal carcinoma, providing a critical new option for this rare and aggressive head and neck cancer.

IOL / Dr. Reddy’s Laboratories

Launch of the Helix Project for Ovarian Cancer Diagnostics

AstraZeneca, in partnership with Thermo Fisher Scientific and major South African pathology laboratories, launched the Helix Project in August 2026 to expand access to advanced diagnostic testing for ovarian cancer, facilitating earlier and more informed treatment decisions.

Engineering News

Expansion of EU-South Africa Collaboration on Nuclear Medicine

The European Union’s Joint Research Centre and the South African Nuclear Medicine Research Infrastructure (NuMeRI) signed a 2025 agreement to accelerate cancer diagnosis and treatment through medical radioisotopes and targeted alpha therapy.

Joint Research Centre (European Commission)

Inaugural CANSA Research Day 2026

The Cancer Association of South Africa (CANSA) hosted its first national Research Day in August 2026, bringing together 58 delegates to foster collaboration and advance translational oncology research across the country.

CANSA

Infrastructure Development in Rural Oncology

Icon Oncology broke ground on a new facility in Springbok in May 2025, aimed at reducing the burden of travel for rural patients and improving access to specialized cancer care in the Namakwaland region.

ICON SA

This section is refreshed on a recurring schedule. Entries are AI-assisted research signals organized from public oncology sources and should be verified against the original sources. Information is educational and does not constitute medical advice.

Huippu Prodigy Platforms

© 2026 Huippu Prodigy Platforms, LLC.

CS Cancer Solutions is operated by Huippu Prodigy Platforms, LLC.

Public-Source Oncology Research • Educational and Research Use

Structured Oncology Research Intelligence